RESEARCHER PROFILE
Associate Professor Amy McCart Reed (Filmed June 2024)
Senior Principal Research Fellow,
Centre for Clinical Research
University of Queensland,
Australia
Associate Professor Amy McCart Reed holds a PhD in molecular biology from The University of Queensland. She is a Fellow of the Faculty of Science of the Royal College of Pathologists Australasia. Her early postdoctoral work focused on understanding the genetic basis of colorectal cancer using experimental disease models, as part of a Cancer Research UK-funded colorectal cancer program led by Professors Ian Tomlinson and Andrew Silver.
After returning to Australia, she was recruited to the Molecular Breast Pathology group at UQ’s Centre for Clinical Research and has undertaken a series of studies investigating the genomic landscape of breast cancer special types. Amy’s research program includes studies on Metaplastic breast cancer and Invasive Lobular Carcinoma, two breast cancer special types in need of targeted therapy options.
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
-
Respiratory health and the microbiome in the lung environment
Dr Taylor leads the Respiratory Health Group within the Microbiome and Host Health Program. His research employs tailored techniques that allow the lung environment to be characterised to a high level of accuracy, including detailed measurements of airway microbiology (microbiome), mucus composition, and inflammation. This information is used to identify predictive markers of chronic lung disease severity as well as determine effective forms of therapy.
-
CASE STUDY Link between levels of extracellular vesicles in the blood and tissue damage caused by diseases
A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.
This study revealed, for the first time, a link between levels of EVs in the blood and tissue damage caused by diseases such as leukaemia.
Researchers hope to leverage the critical new insight to develop a blood test to monitor cancer patients with tissue damage, which could, in future, enhance treatment strategies for blood cancers and other diseases.
-
Lymphoma, Myeloma and Genomics
Professor Dipti Talaulikar is a clinical and laboratory haematologist with expertise in genomics, working at Canberra Health Services, and Professor at ANU. She has a clinical and research interest in lymphoma, myeloma and genomics, and has authored close to 100 peer reviewed papers, including several clinical guidelines that have had a significant impact on clinical practice.
